 GAITHERSBURG, Md., May 19, 2021 GLOBE NEWSWIRE -- NexImmune, Inc. Nasdaq: NEXI, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 12 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology ASCO 2021 Annual Meeting being held virtually from June 4 June 8, 2021. 